These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 32477483)

  • 1. The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis.
    Palmer J; Mesa R
    Ther Adv Hematol; 2020; 11():2040620720925201. PubMed ID: 32477483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
    Patel AA; Odenike O
    Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress of JAK inhibitors for hematological disorders.
    Kirito K
    Immunol Med; 2023 Sep; 46(3):131-142. PubMed ID: 36305377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.
    Bewersdorf JP; Jaszczur SM; Afifi S; Zhao JC; Zeidan AM
    Cancer Manag Res; 2019; 11():10777-10790. PubMed ID: 31920387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
    Saleh K; Ribrag V
    Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of myelofibrosis after ruxolitinib failure.
    Harrison CN; Schaap N; Mesa RA
    Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutics for myelofibrosis.
    Lee SE
    Blood Res; 2023 Apr; 58(S1):S13-S19. PubMed ID: 36891574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [What's new in myeloproliferative neoplasia?].
    Schmidt S; Wolf D
    Dtsch Med Wochenschr; 2022 Mar; 147(6):306-311. PubMed ID: 35291035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of Fedratinib in Routine Treatment of Ruxolitinib-Resistant or -Refractory Patients with Primary and Post-Polycythemia Vera or Essential Thrombocythemia Myelofibrosis: A Nationwide Retrospective Study.
    Duek A; Tzinman A; Maziuk K; Levy A; Ellis M; Stemer G; Shacham Abulafia A; Cohen A; Lavi N; Ronson A; Braester A; Shapira S; Canaani J; Volchek Y; Leiba R; Leiba M
    Acta Haematol; 2024 Sep; ():1-7. PubMed ID: 39265539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Treatment Options for Myelofibrosis: Focus on Anemia.
    Sastow D; Tremblay D
    Ther Clin Risk Manag; 2023; 19():535-547. PubMed ID: 37404252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
    Talpaz M; Kiladjian JJ
    Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How I individualize selection of JAK inhibitors for patients with myelofibrosis.
    Masarova L; Chifotides HT
    Blood; 2024 Oct; ():. PubMed ID: 39357058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis.
    England JT; Gupta V
    Expert Opin Pharmacother; 2022 Oct; 23(15):1677-1686. PubMed ID: 36252265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
    Sureau L; Orvain C; Ianotto JC; Ugo V; Kiladjian JJ; Luque Paz D; Riou J
    Blood Cancer J; 2021 Jul; 11(7):135. PubMed ID: 34315858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
    Pardanani A; Harrison C; Cortes JE; Cervantes F; Mesa RA; Milligan D; Masszi T; Mishchenko E; Jourdan E; Vannucchi AM; Drummond MW; Jurgutis M; Kuliczkowski K; Gheorghita E; Passamonti F; Neumann F; Patki A; Gao G; Tefferi A
    JAMA Oncol; 2015 Aug; 1(5):643-51. PubMed ID: 26181658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.
    Stein BL
    Leuk Lymphoma; 2023 Feb; 64(2):292-299. PubMed ID: 36301740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy.
    Bose P; Kuykendall AT; Miller C; Kurtin S; Farina K; Harting DM; Mascarenhas JO; Mesa RA
    Expert Opin Pharmacother; 2023 Jun; 24(9):1091-1100. PubMed ID: 37163478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
    Tefferi A; Pardanani A; Gangat N
    Am J Hematol; 2024 Feb; 99(2):300-308. PubMed ID: 38164985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.
    Bose P
    Expert Opin Orphan Drugs; 2019; 7(10):415-425. PubMed ID: 33094033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
    Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
    PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.